Eleven Biotherapeutics Company Profile (NASDAQ:EBIO)

About Eleven Biotherapeutics

Eleven Biotherapeutics logoEleven Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company through AMP-Rx, a protein engineering platform, is engaged in the discovery and development of protein therapeutics to treat diseases of the eye. The Company designs, engineers and generates a pipeline of protein therapeutic candidates that target cytokines, which are central to diseases of the eye. The Company is conducting research and development programs directed at both diseases of the front of the eye, such as dry eye disease and allergic conjunctivitis, and diseases of the back of the eye, such as diabetic macular edema (DME) and uveitis. The Company's lead product candidate is EBI-005, a cure for dry eye disease and allergic conjunctivitis. Its preclinical product candidates include EBI-031, a cure for DME, and EBI-028, a cure for uveitis.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: EBIO
  • CUSIP:
Key Metrics:
  • Previous Close: $2.80
  • 50 Day Moving Average: $4.26
  • 200 Day Moving Average: $2.30
  • 52-Week Range: $0.25 - $5.97
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.51
  • P/E Growth: 0.00
  • Market Cap: $43.10M
  • Outstanding Shares: 15,393,000
  • Beta: 3.26
Profitability:
  • Net Margins: -2,995.34%
  • Return on Equity: -207.40%
  • Return on Assets: -126.24%
Debt:
  • Current Ratio: 2.94%
  • Quick Ratio: 2.94%
Additional Links:
Companies Related to Eleven Biotherapeutics:

Analyst Ratings

Consensus Ratings for Eleven Biotherapeutics (NASDAQ:EBIO) (?)
Ratings Breakdown: 2 Hold Ratings
Consensus Rating:Hold (Score: 2.00)
Consensus Price Target: N/A

Analysts' Ratings History for Eleven Biotherapeutics (NASDAQ:EBIO)
Show:
DateFirmActionRatingPrice TargetDetails
1/19/2016Citigroup Inc.DowngradeBuy -> NeutralView Rating Details
1/18/2016Leerink SwannDowngradeOutperform -> Market PerformView Rating Details
(Data available from 9/30/2014 forward)

Earnings

Earnings History for Eleven Biotherapeutics (NASDAQ:EBIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/2/2016        
8/12/2016Q2($0.33)ViewN/AView Earnings Details
3/24/2016Q4($0.32)($0.53)ViewN/AView Earnings Details
11/4/2015Q315($0.33)($0.50)ViewListenView Earnings Details
8/13/2015Q215($0.43)($0.36)ViewListenView Earnings Details
4/30/2015Q115($0.57)($0.36)ViewListenView Earnings Details
3/4/2015Q414($0.33)($0.49)$375.00 millionViewListenView Earnings Details
11/13/2014Q314($0.44)($0.66)ViewN/AView Earnings Details
8/13/2014($0.47)($0.51)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Eleven Biotherapeutics (NASDAQ:EBIO)
Current Year EPS Consensus Estimate: $-1.75 EPS
Next Year EPS Consensus Estimate: $-1.85 EPS

Dividends

Dividend History for Eleven Biotherapeutics (NASDAQ:EBIO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Eleven Biotherapeutics (NASDAQ:EBIO)
Insider Ownership Percentage: 28.70%
Institutional Ownership Percentage: 34.32%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
9/23/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell443,422$3.16$1,401,213.52View SEC Filing  
9/21/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell322,723$3.75$1,210,211.25View SEC Filing  
9/20/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell53,917$3.39$182,778.63View SEC Filing  
9/19/2016Ventures Fund Iv L.P FlagshipMajor ShareholderSell9,700$3.31$32,107.00View SEC Filing  
9/15/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell46,692$4.18$195,172.56View SEC Filing  
9/7/2016Ventures Fund 2007 L FlagshipMajor ShareholderSell129,497$4.54$587,916.38View SEC Filing  
8/15/2016John J MccabeCFOSell1,170$4.80$5,616.00View SEC Filing  
6/27/2016Abbie CelnikerCEOSell10,029$2.08$20,860.32View SEC Filing  
6/27/2016Karen L TubridyInsiderSell4,372$2.08$9,093.76View SEC Filing  
6/13/2016Boxer Capital, LlcMajor ShareholderSell1,042,000$2.74$2,855,080.00View SEC Filing  
2/16/2016John J MccabeSVPSell1,501$0.27$405.27View SEC Filing  
12/28/2015Abbie CelnikerCEOSell10,155$2.85$28,941.75View SEC Filing  
12/28/2015Eric Steven FurfineInsiderSell4,652$2.85$13,258.20View SEC Filing  
5/8/2015Jafco Super V3 Investment LimiMajor ShareholderSell33,400$13.23$441,882.00View SEC Filing  
2/2/2015Jafco Super V3 Investment LimiMajor ShareholderSell17,900$11.62$207,998.00View SEC Filing  
1/30/2015Jafco Super V3 Investment LimiMajor ShareholderSell120,000$11.62$1,394,400.00View SEC Filing  
1/26/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.85$74,655.00View SEC Filing  
1/22/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,300$11.82$74,466.00View SEC Filing  
1/16/2015Jafco Super V3 Investment LimiMajor ShareholderSell6,100$12.07$73,627.00View SEC Filing  
8/26/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.54$23,080.00View SEC Filing  
8/20/2014Jafco Super V3 Investment LimiMajor ShareholderSell1,165$11.54$13,444.10View SEC Filing  
8/18/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,600$11.81$30,706.00View SEC Filing  
8/14/2014Jafco Super V3 Investment LimiMajor ShareholderSell2,000$11.75$23,500.00View SEC Filing  
2/11/2014Jafco Super V3 Investment LimiMajor ShareholderBuy219,790$10.00$2,197,900.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Eleven Biotherapeutics (NASDAQ:EBIO)
DateHeadline
News IconWhat’s Next For Eleven Biotherapeutics Inc (NASDAQ:EBIO)? (NASDAQ:EBIO)
streetregister.com - September 27 at 9:21 AM
News Icon2 Biotech Stocks News And Price Trends: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), Vericel Corporation (NASDAQ ... - The Voice Registrar (NASDAQ:EBIO)
voiceregistrar.com - September 26 at 9:28 AM
News IconBiotech Stocks To Put On Your Watch List: Eleven Biotherapeutics, Inc. (NASDAQ:EBIO), ACADIA Pharmaceuticals Inc ... - The Voice Registrar (NASDAQ:EBIO)
voiceregistrar.com - September 25 at 4:19 PM
News IconEleven Biotherapeutics buys Canadian company (NASDAQ:EBIO)
thelakeandeswave.com - September 24 at 9:23 AM
News IconEleven Biotherapeutics (EBIO) Stock Increases, Buys Viventia Bio (NASDAQ:EBIO)
www.crcconnection.com - September 24 at 9:23 AM
businesswire.com logoEleven Biotherapeutics Reports Inducement Grants Under NASDAQ ... - Business Wire (press release) (NASDAQ:EBIO)
www.businesswire.com - September 23 at 4:31 PM
investopedia.com logoEleven Biotherapeutics Acquires Viventia Bio - Investopedia (NASDAQ:EBIO)
www.investopedia.com - September 23 at 9:45 AM
4-traders.com logoEleven Biotherapeutics : Acquires Viventia Bio to Create Targeted Protein Therapeutics Oncology Company (NASDAQ:EBIO)
www.4-traders.com - September 22 at 4:49 PM
News IconWorth Watching Stocks in Focus: Eleven Biotherapeutics Inc (NASDAQ:EBIO), ConocoPhillips (NYSE:COP) - NYSE Journal (press release) (NASDAQ:EBIO)
stockznews.com - September 22 at 10:19 AM
benzinga.com logoPeregrine Pharmaceuticals Inc. (NASDAQ:PPHM), Eleven ... - Benzinga (NASDAQ:EBIO)
www.benzinga.com - September 22 at 10:19 AM
finance.yahoo.com logoEleven Biotherapeutics Reports Inducement Grants Under NASDAQ ... - Yahoo Finance (NASDAQ:EBIO)
finance.yahoo.com - September 22 at 10:19 AM
businesswire.com logoEleven Biotherapeutics Acquires Viventia Bio to Create Targeted ... - Business Wire (press release) (NASDAQ:EBIO)
www.businesswire.com - September 22 at 10:19 AM
marketwatch.com logoEleven Biotherapeutics stock up 25% on news of Viventia Bio purchase - MarketWatch (NASDAQ:EBIO)
www.marketwatch.com - September 22 at 10:19 AM
investopedia.com logoEleven Biotherapeutics Acquires Viventia Bio (NASDAQ:EBIO)
www.investopedia.com - September 22 at 10:19 AM
247wallst.com logoEleven Bio Finds Even More Pipeline Growth in M&A (NASDAQ:EBIO)
247wallst.com - September 21 at 5:15 PM
investors.com logoEleven Bio beefs up pipeline with Viventia merger (NASDAQ:EBIO)
www.proactiveinvestors.com - September 21 at 5:15 PM
publicnow.com logoEleven Biotherapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) (NASDAQ:EBIO)
www.publicnow.com - September 21 at 5:15 PM
streetinsider.com logoEleven Biotherapeutics (EBIO) Completes Merger with Viventia Bio; New CEO Named (NASDAQ:EBIO)
www.streetinsider.com - September 21 at 9:02 AM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Completion of Acquisitio (NASDAQ:EBIO)
biz.yahoo.com - September 21 at 9:02 AM
publicnow.com logoEleven Biotherapeutics Acquires Viventia Bio to Create Targeted Protein Therapeutics Oncology Company (NASDAQ:EBIO)
www.publicnow.com - September 21 at 9:02 AM
marketwatch.com logoEleven Biotherapeutics stock up 25% on news of Viventia Bio purchase (NASDAQ:EBIO)
www.marketwatch.com - September 21 at 9:02 AM
News IconHC Stocks in Top Row= Eleven Biotherapeutics Inc (EBIO), EXACT Sciences Corporation (NASDAQ:EXAS) - share market updates (press release) (NASDAQ:EBIO)
sharemarketupdates.com - September 9 at 4:36 PM
News IconHere's Where The Real Money Is For Eleven Biotherapeutics Inc (NASDAQ:EBIO) - Street Register (NASDAQ:EBIO)
streetregister.com - September 9 at 4:36 PM
News IconHere’s Where The Real Money Is For Eleven Biotherapeutics Inc (NASDAQ:EBIO) (NASDAQ:EBIO)
streetregister.com - September 9 at 9:33 AM
News IconBiotech Stocks Worth a Closer Look: PDL BioPharma, Inc. (NASDAQ:PDLI), Eleven Biotherapeutics, Inc. (NASDAQ:EBIO) - The Voice Registrar (NASDAQ:EBIO)
voiceregistrar.com - September 2 at 4:40 PM
News Icon2 Biotech Stocks News And Price Trends: Eleven Biotherapeutics ... - The Voice Registrar (NASDAQ:EBIO)
voiceregistrar.com - September 1 at 4:39 PM
News Icon2 Biotech Stocks News And Price Trends: Novavax, Inc. (NASDAQ ... - The Voice Registrar (NASDAQ:EBIO)
voiceregistrar.com - August 25 at 9:43 AM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Completion of Acquisition or Disposition of Assets, Change in Direct (NASDAQ:EBIO)
biz.yahoo.com - August 20 at 8:11 AM
finance.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Financials (NASDAQ:EBIO)
finance.yahoo.com - August 19 at 3:51 PM
News IconIntraday Active Biotech Stocks News: Eleven Biotherapeutics, Inc ... - The Voice Registrar (NASDAQ:EBIO)
voiceregistrar.com - August 18 at 10:04 PM
News IconCisco Systems, Inc. (NASDAQ:CSCO) & Eleven Biotherapeutics (NASDAQ:EBIO) Trending Stocks - Money News (press release) (NASDAQ:EBIO)
www.newsismoney.com - August 17 at 10:03 PM
streetinsider.com logoEleven Biotherapeutics (EBIO) Announces Effectiveness of Exclusive IL-6 Tech Licensing Agreement with Roche (NASDAQ:EBIO)
www.streetinsider.com - August 17 at 4:55 PM
investors.com logoEleven Biotherapeutics advances on Roche licensing (NASDAQ:EBIO)
www.proactiveinvestors.com - August 17 at 4:55 PM
4-traders.com logoEleven Biotherapeutics : Completes Exclusive Licensing Deal for IL-6 Antagonist Antibody Technology, Including EBI-031 (NASDAQ:EBIO)
www.4-traders.com - August 17 at 4:55 PM
News IconBlog Coverage Eleven Biotherapeutics Hits Jackpot Grants Hoffmann-La Roche Exclusive Worldwide License (NASDAQ:EBIO)
news.investornetwork.com - August 17 at 4:55 PM
benzinga.com logo20 Stocks Moving In Tuesday's Pre-Market Session - Eleven ... - Benzinga (NASDAQ:EBIO)
www.benzinga.com - August 17 at 7:16 AM
247wallst.com logoCan Eleven Biotherapeutics Keep Climbing With This Roche Deal? (NASDAQ:EBIO)
247wallst.com - August 16 at 4:48 PM
capitalcube.com logoEleven Biotherapeutics, Inc. :EBIO-US: Earnings Analysis: Q2, 2016 By the Numbers : August 16, 2016 (NASDAQ:EBIO)
www.capitalcube.com - August 16 at 4:48 PM
publicnow.com logoEleven Biotherapeutics Completes Exclusive Licensing Deal for IL-6 Antagonist Antibody Technology, Including EBI-031 (NASDAQ:EBIO)
www.publicnow.com - August 16 at 8:00 AM
marketexclusive.com logoMovers and Shakers in Biotech: Global Blood Therapeutics Inc (NASDAQ:GBT) and Eleven Biotherapeutics Inc (NASDAQ:EBIO) (NASDAQ:EBIO)
marketexclusive.com - August 15 at 4:54 PM
insidermonkey.com logoGlobal Blood Therapeutics (NASDAQ:EBIO)
www.insidermonkey.com - August 15 at 4:54 PM
News IconEleven Biotherapeutics Inc (NASDAQ:EBIO): That’s How We Bought At $3.45 And Now Up Huge 65% Already (NASDAQ:EBIO)
www.marketnewscall.com - August 15 at 4:54 PM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Other Events (NASDAQ:EBIO)
biz.yahoo.com - August 15 at 11:59 AM
News IconStock Earnings Roundup: Eleven Biotherapeutics Inc (NASDAQ:EBIO) - Post Registrar (NASDAQ:EBIO)
postregistrar.com - August 14 at 9:26 AM
finance.yahoo.com logo7:34 am Eleven Biotherapeutics reports Q2 EPS of ($0.33) vs ($0.36) last year; revs $300K versus $100K last year (NASDAQ:EBIO)
finance.yahoo.com - August 12 at 4:47 PM
finance.yahoo.com logo7:34 am Eleven Biotherapeutics reports Q2 EPS of ($0.33) vs ($0.36) last year; revs $300K versus $100K last year (NASDAQ:EBIO)
finance.yahoo.com - August 12 at 4:47 PM
publicnow.com logoEleven Biotherapeutics Reports Second Quarter 2016 Financial Results and Provides Strategic Update (NASDAQ:EBIO)
www.publicnow.com - August 12 at 4:47 PM
publicnow.com logoEleven Biotherapeutics Reports Second Quarter 2016 Financial Results and Provides Strategic Update (NASDAQ:EBIO)
www.publicnow.com - August 12 at 4:47 PM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:EBIO)
biz.yahoo.com - August 12 at 4:47 PM
biz.yahoo.com logoELEVEN BIOTHERAPEUTICS, INC. Files SEC form 8-K, Results of Operations and Financial Condition (NASDAQ:EBIO)
biz.yahoo.com - August 12 at 4:47 PM

Social

Eleven Biotherapeutics (NASDAQ:EBIO) Chart for Friday, September, 30, 2016


Last Updated on 9/30/2016 by MarketBeat.com Staff